Dana-Farber is a leader in the research of precursor hematologic conditions. Our team is committed to early detection and intervention to prevent precursor conditions from progressing to incurable blood cancers. Our center offers patients a range of clinical trials, including screening, treatment, and non-therapeutic trials that will help us to better understand and care for patients with precursor hematologic conditions.
Current Clinical Trials
PROMISE is a screening study for individuals at high-risk of precursor conditions of multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). The goal of this study is to establish a screening method for high-risk individuals and to gather data that helps us understand why some patients progress to myeloma and others do not. Eligibility includes individuals who either have first-degree family members with blood cancers and/or African Americans.